Last10K.com

Integer Holdings Corp (ITGR) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

ITGR Annual Reports

  • 10-K Annual Report February 2022
  • 10-K Annual Report February 2021
    10-K Annual Report February 2020
    10-K Annual Report February 2019
    10-K Annual Report February 2018

Integer Holdings Corp

CIK: 1114483 Ticker: ITGR

EXHIBIT 99.1

Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2021

~ Strong 4Q and Full Year sales and profit increase versus last year ~
~ Completed acquisition of Oscor Inc. ~
~ Generated $157 million cash flow from operations in the full year ~

PLANO, Texas, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three and twelve months ended December 31, 2021. Unless otherwise stated, all results and comparisons are from continuing operations and include the results of operations from Oscor for the period December 1, 2021 through December 31, 2021.

Fourth Quarter 2021 Financial Results (compared to fourth quarter 2020, except as noted)

  • Sales increased 16% to $313 million.
  • GAAP income from continuing operations increased $5 million to $20 million, an increase of 30%. Adjusted net income increased $10 million to $33 million, an increase of 41%.
  • GAAP operating income increased $1 million to $29 million, an increase of 4%. Adjusted operating income increased $6 million to $44 million, an increase of 16%.
  • GAAP diluted EPS from continuing operations increased $0.13 per share to $0.60 per share, an increase of 28%. Adjusted EPS increased $0.28 per share to $0.99 per share, an increase of 39%.
  • Adjusted EBITDA increased $9 million to $58 million, an increase of 19%.
  • In December, completed acquisition of Oscor, a private medical device company headquartered in Florida with significant manufacturing operations in the Dominican Republic.
  • From the end of the third quarter 2021, total debt increased $197 million to $828 million and net total debt increased $206 million to $818 million due to the Oscor acquisition.

Full Year 2021 Financial Results (compared to full year 2020)

  • Sales increased 14% to $1.221 billion.
  • GAAP income from continuing operations increased $16 million to $93 million, an increase of 20%. Adjusted net income increased $44 million to $136 million, an increase of 48%.
  • GAAP operating income increased $15 million to $136 million, an increase of 13%. Adjusted operating income increased $43 million to $187 million, an increase of 30%.
  • GAAP diluted EPS from continuing operations increased $0.47 per share to $2.80 per share, an increase of 20%. Adjusted EPS increased $1.31 per share to $4.08 per share, an increase of 47%.
  • Adjusted EBITDA increased $53 million to $243 million, an increase of 28%.
  • Generated $157 million of cash flow from operating activities.

“Integer delivered strong year-over-year financial results in the fourth quarter and full year 2021 despite a challenging labor and supply chain environment. Looking forward to 2022, we expect our year-over-year sales and profit growth to increase throughout the year. The growth will come from the execution of our strategy as well as the integration of Oscor, which is well underway,” said Joseph Dziedzic, Integer’s president and CEO.

Mr. Dziedzic continued, “During 2021 we protected our associates, delivered for our customers and patients, strengthened our culture, and remained focused on executing our strategy. Integer’s unique position is enabling us to serve our customers through all phases of their products’ lifecycles. Our customers are rewarding us with more development programs in high-growth markets, in support of their product roadmaps. We are confident that our structured and disciplined product line strategy process combined with our targeted investments in high-growth markets will drive sustained above-market growth.”

Discussion of Product Line Fourth Quarter and Full Year Sales

  • Cardio & Vascular sales increased 19% in the fourth quarter 2021 compared to fourth quarter 2020 and full year sales increased 10% year-over-year. Strong double-digit year-over-year sales increases in the fourth quarter across all C&V markets, with particular strength in the neurovascular market, despite end market demand fluctuations and supply chain constraints. Full year sales exceeded 2019 pre-pandemic level, with neurovascular and structural heart both growing double-digits compared to 2019.
  • Cardiac & Neuromodulation sales increased 19% in the fourth quarter 2021 compared to fourth quarter 2020 and full year sales increased 29% year-over-year. Strong year-over-year fourth quarter sales increases across all markets, despite end market demand fluctuations and supply chain constraints, with both Cardiac Rhythm Management and Neuromodulation increasing double-digits. Neuromodulation full year sales exceeded pre-pandemic levels and grew high single-digits compared to 2019 when normalized to exclude $17 million of 2019 sales to Nuvectra. Nuvectra filed for bankruptcy in the fourth quarter of 2019.
  • Advanced Surgical, Orthopedics & Portable Medical includes sales under supply agreement to the acquirer of our divested AS&O product line. Fourth quarter 2021 sales declined 10% compared to fourth quarter 2020 and full year sales decreased 10% year-over-year. Sales decline in the fourth quarter driven by reductions in demand for COVID-related ventilator and patient monitoring components. Full year sales reflect double-digit decline in Advanced Surgical and Orthopedics, the divested product line currently under supply agreement, and low single-digit decline in Portable Medical driven by lower demand for COVID-related ventilators and patient monitoring components.
  • Electrochem sales increased 34% in the fourth quarter 2021 compared to fourth quarter 2020 and full year sales increased 8% year-over-year. Strong fourth quarter growth reflects continued energy market recovery. Full year sales growth reflects moving from a period of energy market contraction to recovery beginning in the second quarter of 2021.

2022 Outlook(a)

  • Sales growth projected to be 10% to 12%, organic growth of 5% - 7%.
    • Expect 1Q22 sales to be similar to 4Q21, constrained by COVID surge impact on labor and supply chain
    • Expect 2Q22 sales to be better than 1Q22 from reduced impact of January’s COVID surge and supply chain volatility
    • Anticipate strong second-half sales growth from improved labor, supply chain, and new product introductions
  • Operating income guidance assumes supply chain and labor constraints improve in the second half.
  • Expect free cash flow to be in the range of $90 to $105 million.

(dollars in millions, except per share amounts)

  GAAP Non-GAAP(b)
  As Reported Change Adjusted Change
Sales $1,340 to $1,365 10% to 12% $1,340 to $1,365 10% to 12%
Operating income $132 to $144 (3)% to 6% $201 to $213 7% to 14%
EBITDA N/A N/A $270 to $282 11% to 16%
Net income $91 to $101 (2)% to 9% $146 to $156 7% to 15%
Earnings per Diluted Share $2.72 to $3.02 (3)% to 8% $4.35 to $4.65 7% to 14%

(a) Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measure for Adjusted operating income, Adjusted EBITDA, Adjusted net income, organic sales growth and Adjusted Earnings per Share (“EPS”), all from continuing operations, and free cash flow, included in our “2022 Outlook” above, and Adjusted interest expense and Adjusted effective tax rate below, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.

(b) Adjusted operating income for 2022 is expected to consist of GAAP operating income, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions and severance, totaling approximately $69 million, pre-tax. Adjusted net income and Adjusted EPS for 2022 are expected to consist of GAAP net income and diluted EPS, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions, severance, gains and losses on equity investments and loss on extinguishment of debt totaling approximately $70 million, pre-tax. The after-tax impact of these items is estimated to be approximately $55 million, or approximately $1.63 per diluted share.

Adjusted EBITDA is expected to consist of Adjusted net income, excluding items such as depreciation, interest, stock-based compensation and taxes totaling approximately $124 to $126 million.

Supplemental Financial Information
(dollars in millions)

 2022
Outlook
 2021
Actual
 
Capital expenditures, net$65 - $75 $53 
Depreciation and amortization$90 - $100 $81 
Stock-based compensation$18 - $21 $16 
Other operating expense$10 - $15 $8 
Adjusted interest expense(a)$24 - $28 $28 
Adjusted effective tax rate(b)16.0% - 17.5% 15% 
Cash tax payments$15 - $20 $20 

(a) Adjusted interest expense refers to our expected full-year GAAP interest expense, expected to range from $25 million to $29 million for 2022, adjusted to remove the full-year impact of charges associated with the write-off of deferred issuance costs and unamortized discounts (loss on extinguishment of debt) included in GAAP interest expense.

(b) Adjusted effective tax rate refers to our full-year GAAP effective tax rate, expected to range from 14.0% to 15.5% for 2022, adjusted to reflect the full-year impact of the items that are excluded in providing adjusted net income and certain other identified items.


Summary Financial Results
(dollars in thousands, except per share data)

 Three Months Ended December 31,
  2021  2020 Change
EBITDA from continuing operations(a)$48,529 $47,540 2.1%
Operating income$28,663 $27,593 3.9%
Income from continuing operations$20,001 $15,427 29.6%
Diluted EPS from continuing operations$0.60 $0.47 27.7%
      
Adjusted EBITDA(a)$58,469 $49,236 18.8%
Adjusted operating income(a)$44,019 $37,975 15.9%
Adjusted net income(a)$33,057 $23,424 41.1%
Adjusted EPS(a)$0.99 $0.71 39.4%
      
 Year Ended December 31,
  2021  2020 Change
EBITDA from continuing operations(a)$214,060 $203,751 5.1%
Operating income$135,711 $120,612 12.5%
Income from continuing operations$93,020 $77,258 20.4%
Diluted EPS from continuing operations$2.80 $2.33 20.2%
      
Adjusted EBITDA(a)$242,983 $189,616 28.1%
Adjusted operating income(a)$187,175 $143,782 30.2%
Adjusted net income(a)$135,550 $91,849 47.6%
Adjusted EPS(a)$4.08 $2.77 47.3%

(a) EBITDA from continuing operations, Adjusted EBITDA, Adjusted operating income, Adjusted net income, and Adjusted EPS are Non-GAAP financial measures. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A, B and C at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.


Summary Product Line Results
(dollars in thousands)

 Three Months Ended December 31,
  2021  2020 Change Organic
Change
(a)
Medical Sales       
Cardio & Vascular$163,381 $137,063 19.2% 17.6%
Cardiac & Neuromodulation 111,869  93,838 19.2% 17.3%
Advanced Surgical, Orthopedics & Portable Medical 26,664  29,747 (10.4)% (10.4)%
Total Medical Sales 301,914  260,648 15.8% 14.3%
Non-Medical Sales 11,101  8,311 33.6% 33.6%
Total Sales$313,015 $268,959 16.4% 14.9%
        
 Year Ended December 31,
  2021  2020  Change Organic
Change
(a)
Medical Sales       
Cardio & Vascular$626,013 $569,948 9.8% 9.0%
Cardiac & Neuromodulation 446,569  346,242 29.0% 28.5%
Advanced Surgical, Orthopedics & Portable Medical 110,044  121,788 (9.6)% (9.6)%
Total Medical Sales 1,182,626  1,037,978 13.9% 13.3%
Non-Medical Sales 38,453  35,464 8.4% 8.4%
Total Sales$1,221,079 $1,073,442 13.8% 13.2%

(a) Organic sales change is a Non-GAAP financial measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts.


Conference Call Information
The Company will host a conference call on Thursday, February 17, 2022, at 8 a.m. CT / 9 a.m. ET to discuss these results. The scheduled conference call will be webcast live and is accessible through our website at investor.integer.net or by dialing (888) 330-3567 (U.S.) or (646) 960-0842 (outside U.S.) and the conference ID is 9252310. The call will be archived on the Company’s website. An earnings call slide presentation containing supplemental information about the Company’s results will be posted to our website at investor.integer.net prior to the conference call and will be referenced during the conference call.

From time to time, the Company posts information that may be of interest to investors on its website at investor.integer.net. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts.

About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.

Contact Information
Tony Borowicz
SVP, Investor Relations
716.759.5809
tony.borowicz@integer.net

Notes Regarding Non-GAAP Financial Information
In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we provide adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted operating income, and organic sales change rates, all from continuing operations. Adjusted net income and adjusted EPS consist of GAAP amounts from continuing operations adjusted for the following to the extent occurring during the period: (i) acquisition and integration related expenses, including fair value adjustments to contingent consideration resulting from acquisitions, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain legal expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) (gain) loss on equity investments, (ix) extinguishment of debt charges, (x) the income tax provision (benefit) related to these adjustments and (xi) certain tax items that are outside the normal tax provision for the period. Adjusted EPS is calculated by dividing adjusted net income by diluted weighted average shares outstanding. EBITDA is calculated by adding back interest expense, provision (benefit) for income taxes from continuing operations, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP financial measure. Adjusted EBITDA consists of EBITDA plus adding back stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (x) and (xi). Adjusted operating income consists of operating income from continuing operations adjusted for the same items listed above except for items (viii), (ix), (x) and (xi).

Organic sales change is reported sales growth adjusted for the impact of foreign currency and the contribution of acquisitions. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue, and exclude the amount of sales acquired or divested during the period from the current/previous period amounts, respectively.

We believe that the presentation of adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA, adjusted operating income, and organic sales change rates, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt, free cash flow and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters. Free cash flow is defined as Net cash provided by operating activities (as stated in our Condensed Consolidated Statements of Cash Flows) reduced by capital expenditures (acquisition of property, plant, and equipment (PP&E), net of proceeds from the sale of PP&E).

Forward-Looking Statements
Some of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to recovery from the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy, including completion and integration of current or future acquisition targets; projected capital spending; and other events, conditions or developments that will or may occur in the future. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “projects,” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors and other risks and uncertainties that arise from time to time are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC and include the following:

  • operational risks, such as the duration, scope and impact of the COVID-19 pandemic, including the evolving health, economic, social and governmental environments and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our reliance on third party suppliers for raw materials, key products and subcomponents; the potential for harm to our reputation caused by quality problems related to our products; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; interruptions in our manufacturing operations; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; our dependence upon our senior management team and technical personnel; and global climate change and the emphasis on ESG matters by various stakeholders;
  • strategic risks, such as the intense competition we face and our ability to successfully market our products; our ability to respond to changes in technology; our ability to develop new products and expand into new geographic and product markets; and our ability to successfully identify, make and integrate acquisitions to expand and develop our business in accordance with expectations;
  • financial risks, such as our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions; financial and market risks related to our international operations and sales; our complex international tax profile; and our ability to realize the full value of our intangible assets; and
  • legal and compliance risks, such as regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability or intellectual property claims; our ability to protect our intellectual property and proprietary rights; our ability and the cost to comply with environmental regulations; our ability to comply with customer-driven policies and third party standards or certification requirements; our ability to obtain necessary licenses for new technologies; legal and regulatory risks from our international operations; and the fact that the healthcare industry is highly regulated and subject to various regulatory changes;

Except as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

Condensed Consolidated Balance Sheets - Unaudited
(in thousands)
  
 December 31,
2021
 December 31,
2020
ASSETS   
Current assets:   
Cash and cash equivalents$17,885 $49,206
Accounts receivable, net 182,310  156,207
Inventories 155,699  149,323
Refundable income taxes 4,735  2,087
Contract assets 64,743  40,218
Prepaid expenses and other current assets 27,610  15,896
Total current assets 452,982  412,937
Property, plant and equipment, net 277,099  253,964
Goodwill 924,704  859,442
Other intangible assets, net 807,810  757,224
Deferred income taxes 5,711  4,398
Operating lease assets 70,053  45,153
Other long-term assets 43,856  38,739
Total assets$2,582,215 $2,371,857
LIABILITIES AND STOCKHOLDERS’ EQUITY   
Current liabilities:   
Current portion of long-term debt$15,250 $37,500
Accounts payable 76,859  51,570
Income taxes payable 725  1,847
Operating lease liabilities 9,862  8,431
Accrued expenses and other current liabilities 56,933  56,843
Total current liabilities 159,629  156,191
Long-term debt 812,876  693,758
Deferred income taxes 171,505  182,304
Operating lease liabilities 59,767  37,861
Other long-term liabilities 23,741  30,688
Total liabilities 1,227,518  1,100,802
Stockholders’ equity:   
Common stock 33  33
Additional paid-in capital 713,150  700,814
Retained earnings 614,324  517,516
Accumulated other comprehensive income 27,190  52,692
Total stockholders’ equity 1,354,697  1,271,055
Total liabilities and stockholders’ equity$2,582,215 $2,371,857


     
Condensed Consolidated Statements of Operations - Unaudited    
(in thousands except per share data)       
    
 Three Months Ended
December 31,
 Year Ended
December 31,
  2021   2020   2021   2020 
Sales$313,015  $268,959  $1,221,079  $1,073,442 
Cost of sales 231,149   195,750   884,109   787,735 
Gross profit 81,866   73,209   336,970   285,707 
Operating expenses:       
Selling, general and administrative (SG&A) 36,268   35,037   141,418   109,006 
Research, development and engineering 12,736   10,589   51,985   48,468 
Other operating expenses (OOE) 4,199   (10)  7,856   7,621 
Total operating expenses 53,203   45,616   201,259   165,095 
Operating income 28,663   27,593   135,711   120,612 
Interest expense 5,511   9,218   31,628   38,220 
(Gain) loss on equity investments, net 1,276   (1,383)  3,143   (5,337)
Other (income) loss, net (252)  1,755   (123)  1,522 
Income from continuing operations before income taxes 22,128   18,003   101,063   86,207 
Provision for income taxes 2,127   2,576   8,043   8,949 
Income from continuing operations$20,001  $15,427  $93,020  $77,258 
        
Discontinued operations:       
Income from discontinued operations before taxes 4,931      4,931    
Provision for income taxes 1,143      1,143    
Income from discontinued operations$3,788  $  $3,788  $ 
        
Net income$23,789  $15,427  $96,808  $77,258 
        
Basic earnings per share:       
Income from continuing operations$0.61  $0.47  $2.82  $2.35 
Income from discontinued operations$0.11  $  $0.11  $ 
Basic earnings per share$0.72  $0.47  $2.93  $2.35 
        
Diluted earnings per share:       
Income from continuing operations$0.60  $0.47  $2.80  $2.33 
Income from discontinued operations$0.11  $  $0.11  $ 
Diluted earnings per share$0.71  $0.47  $2.91  $2.33 
        
Weighted average shares outstanding:       
Basic 33,023   32,880   32,993   32,845 
Diluted 33,280   33,129   33,258   33,113 


 
Condensed Consolidated Statements of Cash Flows(a) - Unaudited
(in thousands)
 Year Ended December 31,
  2021   2020 
Cash flows from operating activities:   
Net income$96,808  $77,258 
Adjustments to reconcile net income to net cash provided by operating activities:   
Depreciation and amortization 81,369   79,324 
Debt related charges included in interest expense 6,954   4,774 
Stock-based compensation 16,185   9,163 
Non-cash (gains) charges related to customer bankruptcy (348)  554 
Non-cash lease expense 8,235   7,810 
Non-cash (gain) loss on equity investments 3,143   (5,337)
Contingent consideration fair value adjustment 133   (2,000)
Other non-cash losses 2,202   600 
Deferred income taxes (10,270)  (6,966)
Changes in operating assets and liabilities, net of acquisitions:   
Accounts receivable (17,539)  38,153 
Inventories 4,700   18,441 
Prepaid expenses and other assets (2,409)  (864)
Contract assets (24,923)  (15,451)
Accounts payable 19,525   (9,055)
Accrued expenses and other liabilities (22,984)  (10,721)
Income taxes payable (4,115)  (4,342)
     Net cash provided by operating activities 156,666   181,341 
Cash flows from investing activities:   
Acquisition of property, plant and equipment (53,463)  (46,832)
Purchase of intangible asset    (4,607)
Proceeds from sale of property, plant and equipment 443   82 
Acquisitions, net (217,978)  (5,219)
     Net cash used in investing activities (270,998)  (56,576)
Cash flows from financing activities:   
Principal payments of term loans (741,786)  (87,500)
Proceeds from issuance of term loans 818,250    
Proceeds from revolving credit facility 82,300   185,000 
Payments of revolving credit facility (63,000)  (185,000)
Proceeds from the exercise of stock options 743   3,263 
Payment of debt issuance costs (8,139)  (515)
Tax withholdings related to net share settlements of restricted stock unit awards (4,592)  (3,820)
Contingent consideration payments (1,621)   
Principal payments on finance leases (169)  (6)
     Net cash provided by (used in) financing activities 81,986   (88,578)
Effect of foreign currency exchange rates on cash and cash equivalents 1,025   (516)
Net increase (decrease) in cash and cash equivalents (31,321)  35,671 
Cash and cash equivalents, beginning of year 49,206   13,535 
Cash and cash equivalents, end of year$17,885  $49,206 

(a) The Condensed Consolidated Statements of Cash Flows - Unaudited includes cash flows related to discontinued operations.


Reconciliations of Non-GAAP Financial Measures from Continuing Operations
Table A: Income from Continuing Operations and Diluted EPS Reconciliations
(dollars in thousands, except per share data)

 Three Months Ended December 31,
  2021   2020 
 Pre-Tax Net of
Tax
 Per
Diluted
Share
 Pre-Tax Net of
Tax
 Per
Diluted
Share
Income from continuing operations (GAAP)$22,128  $20,001  $0.60  $18,003  $15,427  $0.47 
Adjustments(a):           
Amortization of intangibles 10,524   8,323   0.25   10,237   8,095   0.24 
Certain legal expenses (SG&A)(b) 175   139      139   111    
Other operating expenses (OOE)(c) 4,199   3,332   0.10   (10)  235   0.01 
(Gain) loss on equity investments 1,276   1,008   0.03   (1,383)  (1,093)  (0.03)
Loss on extinguishment of debt          550   435   0.01 
Medical device regulations (COS)(d) 270   214   0.01          
Customer bankruptcy(e) (113)  (89)     16   13    
Inventory step-up amortization (COS) 301   266   0.01          
Tax adjustments(f)    (137)        201   0.01 
Adjusted net income (Non-GAAP)$38,760  $33,057  $0.99  $27,552  $23,424  $0.71 
            
Diluted weighted average shares for adjusted EPS   33,280       33,129   
            
 Year Ended December 31,
  2021   2020 
 Pre-Tax Net of
Tax
 Per
Diluted
Share
 Pre-Tax Net of
Tax
 Per
Diluted
Share
Income from continuing operations (GAAP)$101,063  $93,020  $2.80  $86,207  $77,258  $2.33 
Adjustments(a):           
Amortization of intangibles 41,597   32,898   0.99   41,131   32,520   0.98 
Certain legal expenses (gains) (SG&A)(b) 1,454   1,149   0.03   (26,811)  (21,180)  (0.64)
Other operating expenses (OOE)(c) 7,856   6,178   0.19   7,621   6,177   0.19 
(Gain) loss on equity investments 3,143   2,483   0.07   (5,337)  (4,216)  (0.13)
Loss on extinguishment of debt 3,774   2,981   0.09   550   435   0.01 
Medical device regulations (COS)(d) 744   588   0.02          
Customer bankruptcy(e) (488)  (385)  (0.01)  1,229   971   0.03 
Inventory step-up amortization (COS) 301   266   0.01          
Tax adjustments(f)    (3,628)  (0.11)     (116)   
Adjusted net income (Non-GAAP)$159,444  $135,550  $4.08  $104,590  $91,849  $2.77 
            
Diluted weighted average shares for adjusted EPS   33,258       33,113   

(a) The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b) Expenses associated with non-ordinary course legal matters. The full year 2020 also include a net gain of $28.2 million recorded during the third quarter of 2020 in connection with the resolution of the AVX Corporation patent litigation matter.

(c) OOE includes acquisition and integration related expenses, facility consolidation, optimization, manufacturing transfer and system integration charges, asset write-down and disposition charges, charges in connection with corporate realignments or a reduction in force, unusual or infrequently occurring items. OOE for the fourth quarter and full year 2021 includes $2.0 million of acquisition costs related to the acquisition of Oscor. OOE for the fourth quarter and full year 2020 includes a $1.5 million adjustment to reduce the fair value of acquisition-related contingent consideration liabilities.

(d) The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.

(e) In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the “Customer Bankruptcy”). The 2021 amounts are predominantly due to favorable settlements on supplier purchase order termination clauses and benefits recognized from the utilization of previously reserved inventory and the 2020 amounts primarily consist of charges related to inventory recorded in cost of sales in our consolidated statements of operations.

(f) Discrete tax benefits predominately related to the reversal of previously unrecognized tax benefits resulting from the effective settlement of tax audits and the utilization of acquired foreign tax credits during the periods presented.

Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.


Table B: Adjusted Operating Income Reconciliations
(in thousands)

 Three Months Ended
December 31,
 Year Ended
December 31,
  2021   2020   2021   2020 
Operating income (GAAP)$28,663  $27,593  $135,711  $120,612 
Adjustments:       
Amortization of intangibles 10,524   10,237   41,597   41,131 
Certain legal expenses (gains) 175   139   1,454   (26,811)
Other operating expenses 4,199   (10)  7,856   7,621 
Medical device regulations 270      744    
Customer bankruptcy (113)  16   (488)  1,229 
Inventory step-up amortization 301      301    
Adjusted operating income (Non-GAAP)$44,019  $37,975  $187,175  $143,782 
 

Table C: EBITDA Reconciliations
(in thousands)

 Three Months Ended
December 31,
 Year Ended
December 31,
  2021   2020   2021   2020 
Income from continuing operations (GAAP)$20,001  $15,427  $93,020  $77,258 
        
Interest expense 5,511   9,218   31,628   38,220 
Provision for income taxes 2,127   2,576   8,043   8,949 
Depreciation 10,366   10,082   39,772   38,193 
Amortization of intangibles 10,524   10,237   41,597   41,131 
EBITDA from continuing operations (Non-GAAP) 48,529   47,540   214,060   203,751 
Certain legal expenses (gains) 175   139   1,454   (26,811)
Stock-based compensation (excluding OOE) 3,832   2,934   15,913   9,163 
Other operating expenses (OOE) 4,199   (10)  7,856   7,621 
(Gain) loss on equity investments 1,276   (1,383)  3,143   (5,337)
Medical device regulations 270      744    
Customer bankruptcy (113)  16   (488)  1,229 
Inventory step-up amortization 301      301    
Adjusted EBITDA (Non-GAAP)$58,469  $49,236  $242,983  $189,616 
 

Table D: Organic Sales Change Reconciliation (% Change)

 GAAP
Reported
Growth
 Impact of
Acquisitions
and Foreign
Currency
(a)
 Non-GAAP
Organic
Change
Quarter over Quarter Change (4Q 2021 vs. 4Q 2020)     
Medical Sales     
Cardio & Vascular19.2% (1.6)% 17.6%
Cardiac & Neuromodulation19.2% (1.9)% 17.3%
Advanced Surgical, Orthopedics & Portable Medical(10.4)% 
 (10.4)%
Total Medical Sales15.8% (1.5)% 14.3%
Non-Medical Sales33.6% 
 33.6%
Total Sales16.4% (1.5)% 14.9%
      
Year over Year Change (2021 vs. 2020)     
Medical Sales     
Cardio & Vascular9.8% (0.8)% 9.0%
Cardiac & Neuromodulation29.0% (0.5)% 28.5%
Advanced Surgical, Orthopedics & Portable Medical(9.6)% 
 (9.6)%
Total Medical Sales13.9% (0.6)% 13.3%
Non-Medical Sales8.4% 
 8.4%
Total Sales13.8% (0.6)% 13.2%

(a) Fourth quarter and full year 2021 and 2020 sales have been adjusted to exclude the contribution of business acquisitions and foreign currency exchange rate fluctuations.


Table E: Net Total Debt Reconciliation
(in thousands)

 December 31,
2021
 October 1,
2021
 December 31,
2020
Total debt 828,126  630,655  731,258
Add: Unamortized discount and deferred debt issuance costs 7,361  6,645  6,715
Total principal amount of debt outstanding 835,487  637,300  737,973
LESS: Cash and cash equivalents 17,885  25,472  49,206
Net Total Debt (Non-GAAP)$817,602 $611,828 $688,767

 


The following information was filed by Integer Holdings Corp (ITGR) on Thursday, February 17, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Integer Holdings Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Integer Holdings Corp.

Continue

Assess how Integer Holdings Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Integer Holdings Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
M & A
Revenue
Other
Filter Subcategory:
All
Earnings
Product
Expense
Debt
Cash Flow
Shares
Geography
Income
Other
Inside Integer Holdings Corp's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Stockholders' Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Operations
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Details)
Accrued Expenses And Other Current Liabilities (Tables)
Benefit Plans
Benefit Plans (Defined Benefit Plans Narrative) (Details)
Benefit Plans (Savings Plan Narrative) (Details)
Business Acquisition
Business Acquisition ( Pro Forma Information) (Details)
Business Acquisition (Acquisition Of Assets From Inomec Ltd Narrative) (Details)
Business Acquisition (Acquisition Of Assets From Oscor Inc Narrative) (Details)
Business Acquisition (Acquisition Of Assets From Us Biodesign Llc Narrative) (Details)
Business Acquisition (Allocation Of The Provisional Purchase Price ) (Details)
Business Acquisition (Indefinite-Lived Intangible Assets) (Details)
Business Acquisition (Tables)
Commitments And Contingencies
Commitments And Contingencies (Change In Product Warranty Liability) (Details)
Commitments And Contingencies (Narrative) (Details)
Commitments And Contingencies (Tables)
Debt
Debt (Covenants) (Details)
Debt (Deferred Debt Issuance Costs And Discounts) (Details)
Debt (Deferred Financing Fees) (Details)
Debt (Long-Term Debt Maturity Schedule) (Details)
Debt (Revolving Credit Facility) (Details)
Debt (Schedule Of Long-Term Debt) (Details)
Debt (Senior Secured Credit Facilities) (Details)
Debt (Tables)
Debt (Term Loan Facilities) (Details)
Discontinued Operations
Discontinued Operations (As&Amp;O Business Narrative) (Details)
Discontinued Operations (Cash Flow Information From Discontinued Operations) (Details)
Discontinued Operations (Income From Discontinued Operations) (Details)
Discontinued Operations (Tables)
Earnings Per Share
Earnings Per Share (Antidilutive Securities) (Details)
Earnings Per Share (Details)
Earnings Per Share (Tables)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Assets And Liabilities Recorded At Fair Value On A Recurring Basis) (Details)
Financial Instruments And Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details)
Financial Instruments And Fair Value Measurements (Equity Method Investments) (Details)
Financial Instruments And Fair Value Measurements (Estimated Fair Values For Contingent Consideration) (Details)
Financial Instruments And Fair Value Measurements (Narratives) (Details)
Financial Instruments And Fair Value Measurements (Schedule Of Derivative Instruments With Hedge Accounting Designation) (Details)
Financial Instruments And Fair Value Measurements (Schedule Of Foreign Currency Contracts) (Details)
Financial Instruments And Fair Value Measurements (Schedule Of Interest Rate Swaps) (Details)
Financial Instruments And Fair Value Measurements (Tables)
Goodwill And Other Intangible Assets, Net
Goodwill And Other Intangible Assets, Net (Amortization Expense By Categories) (Details)
Goodwill And Other Intangible Assets, Net (Future Amortization Expense) (Details)
Goodwill And Other Intangible Assets, Net (Narrative) (Details)
Goodwill And Other Intangible Assets, Net (Schedule Of Intangible Assets) (Details)
Goodwill And Other Intangible Assets, Net (Tables)
Goodwill And Other Intangible Assets, Nets (Schedule Of Goodwill) (Details)
Income Taxes
Income Taxes (Deferred Tax Assets And Liabilities) (Details)
Income Taxes (Effect Tax Rate Reconciliation) (Details)
Income Taxes (Income Before Income Tax Domestic And Foreign) (Details)
Income Taxes (Income Tax Carry Forward) (Details)
Income Taxes (Narrative) (Details)
Income Taxes (Provision Benefit Of Income Taxes) (Details)
Income Taxes (Tables)
Income Taxes (Unrecognized Tax Benefits) (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Leases
Leases (Lease Term And Discount Rate) (Details)
Leases (Narrative) (Details)
Leases (Schedule Of Lease Costs) (Details)
Leases (Schedule Of Operating Lease Liability Maturities) (Details)
Leases (Schedule Of Operating Lease Supplemental Cash Flow Information) (Details)
Leases (Tables)
Other Operating Expenses
Other Operating Expenses (Changes In Accrued Liabilities) (Details)
Other Operating Expenses (Narrative) (Details)
Other Operating Expenses (Schedule Of Other Operating Expenses) (Details)
Other Operating Expenses (Tables)
Property, Plant And Equipment, Net
Property, Plant And Equipment, Net (Depreciation Expense) (Details)
Property, Plant And Equipment, Net (Details)
Property, Plant And Equipment, Net (Tables)
Revenue From Contracts With Customers
Revenue From Contracts With Customers (Contract Balances) (Details)
Revenue From Contracts With Customers (Disaggregated Revenue) (Details)
Revenue From Contracts With Customers (Tables)
Schedule Ii - Valuation And Qualifying Accounts
Schedule Ii - Valuation And Qualifying Accounts (Details)
Segment And Geographic Information
Segment And Geographic Information (Long Lived Tangible Assets By Region) (Details)
Segment And Geographic Information (Narrative) (Details)
Segment And Geographic Information (Reconciliation Of Segment Information) (Details 1)
Segment And Geographic Information (Sales By Geographic Information) (Details)
Segment And Geographic Information (Sales By Product Lines) (Details)
Segment And Geographic Information (Schedule Of Revenue By Ship To Location) (Details)
Segment And Geographic Information (Significant Customers) (Details)
Segment And Geographic Information (Tables)
Stock-Based Compensation
Stock-Based Compensation (Components Of Stock-Based Compensation Expense) (Details)
Stock-Based Compensation (Exercise Of Stock Option) (Details)
Stock-Based Compensation (Narratives) (Details)
Stock-Based Compensation (Restricted Stock And Restricted Stock Units) (Details)
Stock-Based Compensation (Stock Option Activity) (Details)
Stock-Based Compensation (Tables)
Stock-Based Compensation (Weighted-Average Fair Value And Assumptions) (Details)
Stockholders' Equity
Stockholders' Equity (Schedule Of Accumulated Other Comprehensive Income) (Details)
Stockholders' Equity (Schedule Of Changes In Number Of Shares Of Common Stock) (Details)
Stockholders' Equity (Tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Narrative) (Details)
Summary Of Significant Accounting Policies (Policies)
Supplemental Cash Flow Information
Supplemental Cash Flow Information (Details)
Supplemental Cash Flow Information (Tables)
Ticker: ITGR
CIK: 1114483
Form Type: 10-K Annual Report
Accession Number: 0001114483-22-000002
Submitted to the SEC: Tue Feb 22 2022 7:33:51 AM EST
Accepted by the SEC: Tue Feb 22 2022
Period: Friday, December 31, 2021
Industry: Miscellaneous Electrical Machinery Equipment And Supplies

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/itgr/0001114483-22-000002.htm